Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: NCT05209789. We help you review the study, but cannot decide medical eligibility.
CompletedNCT05209789
Early Intervention to Protect the Mother-Child Relationship After Postpartum Depression
This study is completed. It focuses on depression and currently lists study information in France.
DepressionOtherFrom 18 Years to 100 Years
Key information made simple
What is this study testing?
This study is testing whether the study approach may be useful for children experiencing depression.
What would participation involve?
Participants may complete study activities around the study approach, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in France.
Who is it mainly for?
This study appears to be mainly for children with depression. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record suggests in-person participation through a hospital, with sites including Bordeaux Public Hospital, Havre Public Hospital Maternity in Le Havre, and Reims Public Hospital Maternity. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and matching the main diagnosis. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 18, 2023
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- University Hospital, Toulouse
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- France
- Age range
- From 18 Years to 100 Years
- Official registry ID
- NCT05209789
- Official title
- Early Intervention to Protect the Mother-Child Relationship After Postpartum Depression
- Official source
- Official registry link
Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: NCT05209789. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in France.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 100 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by University Hospital, Toulouse, which appears to be a hospital or academic medical center. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2019-001989-15
Fremanezumab for Depression
This study is completed in France, in Germany, in Czechia, .... It is testing fremanezumab for Depression.
CompletedNCT05841030
A Study in people with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
This study is completed in the United States, in France, in Canada, .... It focuses on depression.
CompletedNCT05550532
Aticaprant 10 Milligrams (mg) for Depression
This study is completed in the United States, in France, in Canada, .... It is testing Aticaprant 10 Milligrams (mg) for Depression.